Your browser version may not work well with NCBI's Web applications. More information
here...
-
Effects of bimatoprost 0.03% on ocular hemodynamics in normal tension glaucoma.
Department of Ophthalmology, Taipei Veterans General Hospital, Taiwan. mj_chen@vghtpe.gov.tw
PURPOSE: The aim of this study was to investigate the effects of bimatoprost 0.03% on ocular hemodynamics in patients with normal tension glaucoma (NTG). METHODS: Twenty-two (22) patients with NTG were consecutively recruited. After basic eye examination and diurnal intraocular pressure (IOP) measurement, color Doppler imaging was used to measure the peak systolic and end diastolic velocities and resistive index of the central retinal, lateral posterior ciliary, and medial posterior ciliary arteries. Patients received bimatoprost 0.03% for 4 weeks, and these measurements were then repeated. The worse eye of each NTG patient was used in the statistical analysis. RESULTS: Bimatoprost 0.03% significantly reduced mean IOP from 15.1 +/- 3.8 mmHg at baseline to 12.0 +/- 2.9 mmHg after treatment in our sample of NTG patients (P < 0.001). No significant changes in blood velocities or resistance indices were observed in the retrobulbar vessels after the 4-week treatment. CONCLUSIONS: Topical bimatoprost 0.03% significantly reduced IOP in our NTG patients without causing significant hemodynamic changes in the retrobulbar vessels.
PMID: 16808680 [PubMed - indexed for MEDLINE]
-
Related Articles
-
Patient Drug Information
-
Bimatoprost Ophthalmic (Lumigan®)
Bimatoprost is used to treat eye conditions, including glaucoma and ocular hypertension, in which increased pressure can lead to a gradual loss of vision. Bimatoprost is used for patients who cannot use other eye medicat...